Novella Clinical Adds Jon Gockerman, MD as Senior Medical Director for Oncology

Novella Clinical Adds Jon Gockerman, MD as Senior Medical Director for Oncology

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Novella Clinical, a full service clinical research organization, today announced Jon P. Gockerman, MD, has joined as senior medical director for oncology within its dedicated Oncology Division.

"We are fortunate to bring Jon's expertise and knowledge to Novella to further enhance our growing oncology division and medical oncology CRO services."
A board-certified hematologist/oncologist, Duke University Professor Emeritus Jon Gockerman joined Novella following 30 years of oncology and hematology research and clinical practice at Duke's Department of Medicine.

Dr. Gockerman's clinical research focused on designing, implementing and evaluating oncology studies in areas of both solid tumors and hematologic malignancies, including breast, lung, colon, testicular, renal and sarcoma indications, as well as acute and chronic leukemia and myeloma. Working closely with the phase I group at Duke, Dr. Gockerman also completed a number of new drug discovery studies with pharamakinetics and molecular analysis in lymphomas, including pazopanib, which gained approval for renal cell carcinoma and soft tissue sarcoma by the U.S. Food and Drug Administration.

His many accolades include earning the 2012 Leonard B. Tow Humanism in Medicine Award and the Master Clinician/Teacher Award by Duke University Medical Center in 2008, honoring his work in clinical areas as well as mentoring and teaching medical students. Dr. Gockerman earned the Wendell F. Rosse fellowship teaching award three times while at Duke, and authored over one hundred peer-reviewed publications most of which relate to clinical research or clinical laboratory questions. A member of the Cancer and Leukemia Group B, a national clinical research group sponsored by the National Cancer Institute, Dr. Gockerman also serves on the National Comprehensive Cancer Network committee on lymphoma and cancers of unknown origin.

Novella Clinical Chief Medical Officer Frank Santoro, MD, noted, "We are fortunate to bring Jon's expertise and knowledge to Novella to further enhance our growing oncology division and medical oncology CRO services."

Dr. Gockerman earned his undergraduate degree from the University of Michigan and attended medical school at the University of Chicago. He completed his internal medicine and fellowship training at Duke University. Prior to returning to Duke he held positions at Walter Reed Army Institute of Research, University of Kentucky and University of Alabama in Birmingham.

About Novella Clinical

Novella Clinical, Inc. is a full service clinical research organization with dual headquarters in Research Triangle Park, N.C and Stevenage, England. Celebrating its 15th anniversary, Novella serves as an active partner to the oncology, biopharma and medical device industries. As the first global eCRO, Novella integrates deep clinical expertise with industry-leading technologies and a proven approach to support, streamline and expertly resource the entire product development process. For more information, visit www.novellaclinical.com.

 

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.